Company intelligence / Profile preview

Zhejiang VDJ Bio-Technology

Beijing, Beijing Shi, Chinacn.linkedin.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

The company has completed a Phase II trial for VDJ-001 (tocilizumab biobetter) in rheumatoid arthritis and is planning a Phase III trial as of December 2024. Efficacy and adverse events data from the Phase II trial were presented at the 25th Annual Congress of the European League Against Rheumatism in July 2024.

Therapeutic areas: GastroenterologyImmunologyHematology
Modalities: Monoclonal antibodiesFusion proteins
Industry: Biotech

Beyond the preview

Go deeper on Zhejiang VDJ Bio-Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhejiang VDJ Bio-Technology.

Explore the full profile